Prof. Erez Levanon Prof. Erez Levanon is a Senior Lecturer in the Mina and Everard Goodman Faculty of Life Sciences and recipient of the Alon Fellowship for 2011. Erez Levanon came to Bar-Ilan University from Harvard Medical School as part of the 2009 cohort of returning scientists, a special program within Bar-Ilan University to recruit young Israeli scientists to return to work in Israel. Prof. Levanon published more than 80 research papers which were quoted over 7500 Prof. Levanon published more than 80 research papers which were quoted over 7500 times. He authored patents in the field of genome engineering .

In recent years, targeted immune therapies are emerging as standard treatments for advanced-stage cancers. These drugs target cell surface checkpoint proteins to stimulate the recognition and destruction of cancer cells by the immune system. Nevertheless, while the immune checkpoint blockade approach can induce durable responses across multiple types of malignancies, these remarkable responses are currently limited to a minority of patients.

By identifying specific inhibitors for ADAR, a novel key player in immunotherapy resistance, targeted immune therapies will be applicable for a larger number of patients.

ADAR inhibitors can be utilized to find molecules that can overcome the resistance to immune checkpoint blockade, and enable more patients to benefit from the most effective anti-cancer therapy available today.

The global immune checkpoint inhibitors market was valued at USD 10,566 million in 2017, and is expected to reach USD 56,530 million by 2025, with a CAGR of 20.1% from 2018 to 2025. The market growth is driven by the rise in prevalence of cancer across geographies, the growing awareness of immune checkpoint inhibitors, the technological advancements in screening procedure for cancer, increased healthcare expenditures and increase in government initiatives to alleviate cancer.

Oncology/Cancer Drugs marketCancer immunotherapy marketBiotech companies

Patent pending

Further develop algorithms to uncover the full extent of A-to-I RNA editing

We are looking for investors that are willing to support the research and commercialize this novel invention.

ADAR Genome editing Immune checkpoint blockade Immunotherapy

ADAR inhibitors to suppress resistance to immune checkpoint inhibitors